Global Gastrointestinal OTC Drugs Market Report and Forecast 2024-2032

Global Gastrointestinal OTC Drugs Market Outlook

The global gastrointestinal OTC drugs market size was valued at USD 41.96 billion in 2023, driven by the increasing awareness of gastrointestinal diseases among people across the globe. The market size is anticipated to grow at a CAGR of 4.9% during the forecast period of 2024-2032 to achieve a value of USD 64.5 billion by 2032.

Gastrointestinal OTC Drugs: Introduction

Gastrointestinal diseases impact the entire gastrointestinal (GI) tract, spanning from the mouth to the anus. The prevalent GI disorders include irritable bowel syndrome (IBS), acid reflux, indigestion, colon cancer, and hemorrhoids, each of these conditions affect different parts of the digestive passage. The GI tract plays a crucial role in digestion, breaking down food, and facilitating nutrient absorption to maintain overall health. However, numerous GI diseases disrupt this process, interfering with the body's ability to effectively digest consumed food, potentially leading to various health complications.

To address these conditions, there are medications specifically designed for managing GI disorders, available both by prescription and over the counter. These over-the-counter gastrointestinal drugs (GI OTC drugs) aim to alleviate symptoms and manage the discomfort associated with these conditions, providing relief and support for individuals dealing with gastrointestinal issues.

Global Gastrointestinal OTC Drugs Market Analysis

The market is witnessing significant growth driven by various factors and recent advancements. Clinical trials play a pivotal role in uncovering new therapies and diagnostic tools to handle a wide range of gastrointestinal (GI) disorders, showcasing the constant evolution in treatment methodologies, further driving the market growth. The market growth is further influenced by the increasing comprehension and the number of FDA approvals exemplified by the FDA's recent approval of ‘Upadacitinib’ for treating moderately to severely active Crohn's disease. This FDA approval has marked an important milestone, following successful trials assessing its efficacy and safety, further bolstering the gastrointestinal OTC drugs market growth.

Continuous research efforts have also emphasized the importance of targeted strategies for treating gastroesophageal reflux disease (GERD) and preventing potential long-term complications. Interventional endoscopy, showing promising potential, is anticipated to shape the forecast period for GERD management as well.

Moreover, ongoing developments in the pharmaceutical sector are evident in contributing to the market growth. For instance, the New Drug Application (NDA) for Vonoprazan, the Phase 3 study of this drug showcased its efficacy and safety as a daily treatment for Non-Erosive GERD in adults. This investigational potassium-competitive acid blocker (PCAB) represents a novel class of medicines targeting acid secretion in the stomach, highlighting the dedicated interest in innovative solutions among the researchers, and contributing significantly to the growing gastrointestinal OTC drugs market share.

The combination of targeted therapies, microbiome research, and novel pharmaceutical submissions underscores a dynamic shift in GI disorder treatments, driving the growth of the global GI OTC drugs market. These advancements substantially expand treatment options coupled with a broader understanding and approach toward managing gastrointestinal conditions.

Global Gastrointestinal OTC Drugs Market Segmentations

Market Breakup by Class

• Antacids

• Laxatives

• Anti-Diarrheal

• Anti-Emetics

• Others

Market Breakup by Indication

• Heartburn

• Diarrhea

• Constipation

• Gastroesophageal Reflux Disease

• Others

Market Breakup by End User

• Hospitals

• Clinics

• Home Healthcare

• Others

Market Breakup by Region

• North America

• Europe

• Asia Pacific

• Latin America

• Middle East and Africa

Global Gastrointestinal OTC Drugs Market Overview

The market has been witnessing robust growth driven by several key factors such as the escalating incidence of gastrointestinal issues among people worldwide. This surge in prevalence increases the demand and need for over-the-counter OTC drugs, valued for their cost-effectiveness and easy accessibility. Gastrointestinal therapeutics are further benefiting from ongoing research and development innovations, fostering the development of advanced drugs, and thereby escalating the gastrointestinal OTC drugs market demand. Moreover, the burgeoning trend of self-diagnosis and self-medication is contributing to the demand for these OTC remedies.

Based on regions, North America is currently dominating the gastrointestinal OTC drugs market and is expected to continue dominating the market in the forecast period as well. The growth of the regional market is expected to be driven by the presence of robust healthcare infrastructure and favourable reimbursement policies. The region's high healthcare expenditure highlights its dominance in the global market for gastrointestinal OTC drugs.

Global Gastrointestinal OTC Drugs Market: Competitor Landscape

The key features of the market report include patent analysis, grants analysis, clinical trials analysis, funding and investment analysis, partnerships, and collaborations analysis by the leading key players. The major companies in the market are as follows:

• Mylan N.V.

• Sandoz AG

• Johnson & Johnson Services

• Sun Pharmaceuticals Industries

• Teva Pharmaceuticals Industries

• Zydus Cadila

• Sanofi

• Bayer AG

• Pfizer Inc.

• Amneal Pharmaceutical Inc.

• Procter & Gamble

• Hikma Pharmaceutical PLC

• Perrigo Pharmaceutical Plc.

• Abbott

• Lupin

Please note that this only represents a partial list of companies, and the complete list has been provided in the report.

Key Highlights of the Report